Ads
related to: crispr/cas9
Search results
Mitsubishi UFJ Asset Management Co. Ltd. Has $218,000 Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
ETF DAILY NEWS· 22 hours agoMitsubishi UFJ Asset Management Co. Ltd. lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 22.4% during the fourth quarter, according ...
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 3 days agoWith a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (NASDAQ: CRSP) is...
Chutes & Ladders—CRISPR Therapeutics finds new CMO in Sanofi leader
FierceBiotech· 17 hours agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%
ETF DAILY NEWS· 6 days agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price dropped 0.3% during mid-day trading on Friday . The company traded as low as $54.64 and last traded at ...
ERS Genomics and IRBM sign CRISPR / Cas9 license agreement
BioPharma-Reporter· 5 days agoCRISPR licensing company ERS Genomics and drug discovery firm IRBM have entered into a non-exclusive...
The Realities And Ethics Of Pig Organ Transplants In Humans : 1A
NPR· 1 day agoWith CRISPR technology, scientists can edit pig genes to be more compatible with a human body, or at...
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
The Motley Fool via AOL· 3 days agoLet's check out these two bull market buys to own for the long run. Image source: Getty Images. 1. ...
Idorsia’s Jean-Paul Clozel retires as CEO, plots next steps; CRISPR Therapeutics nabs CMO from...
Endpoints News· 18 hours ago→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether. Jörn Aldag, Felix Ehrat and Peter Kellogg are stepping ...
Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 4 days agoCathie Wood is famous for her singular investing style. Favoring high growth and disruptors, she...
In Brief This Week: ERS Genomics, Lunit, Agilent, Thermo Fisher, Congenica, Oxford BioDynamics, More
GenomeWeb News· 15 hours agoERS Genomics this week said it has signed a nonexclusive licensing agreement for CRISPR-Cas9 patents with Italian contract research organization IRBM. Lunit will integrate ...